Premium
Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcγRI), blocks phagocytosis, and modulates receptor expression
Author(s) -
Wallace Paul K.,
Keler Tibor,
Coleman Kimberly,
Fisher Jan,
Vitale Laura,
Graziano Robert F.,
Guyre Paul M.,
Fanger Michael W.
Publication year - 1997
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.62.4.469
Subject(s) - cd64 , monoclonal antibody , biology , fc receptor , opsonin , antibody , receptor , immunoglobulin g , immune system , cd16 , phagocytosis , immunology , microbiology and biotechnology , biochemistry , cd3 , cd8
About 10–15% of patients with immune thrombocytopenic purpura (ITP) cannot be controlled by corticosteroid therapy and splenectomy. For these patients treatment with high‐dose IVIgG induces partial or complete responses. The clinical benefits of IVIgG could be due to blockade of Fc receptors for IgG (FcγR), because several model systems clearly show that functional FcγR are essential for establishment of ITP and related diseases. However, the specific contributions of the three individual classes of FcγR remain to be more completely defined. Recently monoclonal antibody (mAb) H22, which recognizes an epitope on FcγRI (CD64) outside the ligand binding domain, was humanized by grafting its complementarity determining regions onto human IgG1 constant domains. Because FcγRI has a high affinity for human IgG1 antibodies, we predicted mAb H22 would also bind to FcγRI through its Fc domain and block FcγRI‐mediated phagocytosis. These studies demonstrate that mAb H22 blocked phagocytosis of opsonized red blood cells 1000 times more effectively than an irrelevant IgG. Moreover, cross‐linking FcγRI with mAb H22 rapidly down‐modulated FcγRI expression on monocytes without affecting other surface antigens. We conclude that because mAb H22 is a humanized mAb that blocks the FcγRI ligand binding domain and down‐modulates FcγRI expression, it is a particularly good candidate for evaluating the role of FcγRI in patients with ITP. J. Leukoc. Biol. 62:469–479; 1997.